The US FDA has urgently authorized Pfizer and MSD anti Novel COVID-19 oral drugs to go on the market

The US FDA has urgently authorized Pfizer and MSD anti Novel COVID-19 oral drugs to go on the market In December 22nd, novel coronavirus pneumonia Paxlovid was approved by the US Food and Drug Administration (FDA). The emergency use authorization of Pfizer was applied within 5 days after symptoms appeared. It was used to treat severe acute lung cancer patients aged 12 and above. Meanwhile, novel coronavirus pneumonia was used by FDA to authorize the use of mercad Molnupiravir in December 23rd. It is the second newly approved oral medicine for patients with high risk and no other…

Pfizer opens anti neocrown generic drugs for low – and middle-income countries! Experts say the vaccine should also be opened

Pfizer opens anti neocrown generic drugs for low - and middle-income countries! Experts say the vaccine should also be opened.Pfizer's official website released Pfizer will sign a voluntary license agreement against COVID-19's oral drug candidate PF-07321332 in Geneva in November 16th. According to the agreement, the world's qualified generic drug manufacturers can produce PF-07321332 drugs to 95 countries, covering about 53% of the world's population

Pfizer said a third dose of vaccine could prevent Omicron infection

On December 7, the African Institute of health released information that the neutralizing antibody titer against Omicron variant in two doses of Pfizer vaccine was 41 times lower than that of the original strain, which attracted global attention. Pfizer released similar data the next day, saying that the antibody titer decreased 25 times, and two doses of vaccine may not be enough to prevent Omicron infection.